Julius Duic

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Journal of Clinical Oncology · 2009 · 1,277 citations

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Journal of Translational Medicine · 2018 · 425 citations